127 related articles for article (PubMed ID: 31441600)
1. Low expression of TET2 gene in pediatric acute lymphoblastic leukemia is associated with poor clinical outcome.
Zhang P; Weng WW; Chen P; Zhang Y; Ruan JF; Ba DD; Xu WQ; Tang YM
Int J Lab Hematol; 2019 Oct; 41(5):702-709. PubMed ID: 31441600
[TBL] [Abstract][Full Text] [Related]
2. TET2 expression is a potential prognostic and predictive biomarker in cytogenetically normal acute myeloid leukemia.
Zhang TJ; Zhou JD; Yang DQ; Wang YX; Wen XM; Guo H; Yang L; Lian XY; Lin J; Qian J
J Cell Physiol; 2018 Aug; 233(8):5838-5846. PubMed ID: 29219176
[TBL] [Abstract][Full Text] [Related]
3. TET2 Promoter DNA Methylation and Expression in Childhood Acute Lymphoblastic Leukemia.
Bahari G; Hashemi M; Naderi M; Taheri M
Asian Pac J Cancer Prev; 2016; 17(8):3959-62. PubMed ID: 27644645
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of lymphoid enhancer-binding factor-1 (LEF1) is a novel favorable prognostic factor in childhood acute lymphoblastic leukemia.
Jia M; Zhao HZ; Shen HP; Cheng YP; Luo ZB; Li SS; Zhang JY; Tang YM
Int J Lab Hematol; 2015 Oct; 37(5):631-40. PubMed ID: 25955539
[TBL] [Abstract][Full Text] [Related]
5. MYC deregulates TET1 and TET2 expression to control global DNA (hydroxy)methylation and gene expression to maintain a neoplastic phenotype in T-ALL.
Poole CJ; Lodh A; Choi JH; van Riggelen J
Epigenetics Chromatin; 2019 Jul; 12(1):41. PubMed ID: 31266538
[TBL] [Abstract][Full Text] [Related]
6. The prognostic impact of tet oncogene family member 2 mutations in patients with acute myeloid leukemia: a systematic-review and meta-analysis.
Wang R; Gao X; Yu L
BMC Cancer; 2019 Apr; 19(1):389. PubMed ID: 31023266
[TBL] [Abstract][Full Text] [Related]
7. [Clinical significance of TET2 gene expression in 157 adult acute myeloid leukemia patients with normal cytogenetics].
Zhu Z; Chen J; Yu M; Chen F; Chen Z; Lou J; Tong H; Huang J; Qian W; Meng H; Jin J
Zhonghua Xue Ye Xue Za Zhi; 2014 Sep; 35(9):802-7. PubMed ID: 25246247
[TBL] [Abstract][Full Text] [Related]
8. Tet oncogene family member 2 gene alterations in childhood acute myeloid leukemia.
Li MJ; Yang YL; Lee NC; Jou ST; Lu MY; Chang HH; Lin KH; Peng CT; Lin DT
J Formos Med Assoc; 2016 Sep; 115(9):801-6. PubMed ID: 26414667
[TBL] [Abstract][Full Text] [Related]
9. Low Ten-eleven-translocation 2 (TET2) transcript level is independent of TET2 mutation in patients with myeloid neoplasms.
Scopim-Ribeiro R; Machado-Neto JA; de Melo Campos P; Niemann FS; Lorand-Metze I; Costa FF; Olalla Saad ST; Traina F
Diagn Pathol; 2016 Mar; 11():28. PubMed ID: 26984174
[TBL] [Abstract][Full Text] [Related]
10. U2AF1 expression is a novel and independent prognostic indicator of childhood T-lineage acute lymphoblastic leukemia.
Zhang P; Zhang Y; Li X; Ying P; Tang Y
Int J Lab Hematol; 2021 Aug; 43(4):675-682. PubMed ID: 33314767
[TBL] [Abstract][Full Text] [Related]
11. Ten-eleven-translocation 2 (TET2) is downregulated in myelodysplastic syndromes.
Scopim-Ribeiro R; Machado-Neto JA; Campos Pde M; Silva CA; Favaro P; Lorand-Metze I; Costa FF; Saad ST; Traina F
Eur J Haematol; 2015 May; 94(5):413-8. PubMed ID: 25200248
[TBL] [Abstract][Full Text] [Related]
12. Expression and prognostic significance of livin/BIRC7 in childhood acute lymphoblastic leukemia.
Ibrahim L; Aladle D; Mansour A; Hammad A; Al Wakeel AA; Abd El-Hameed SA
Med Oncol; 2014 May; 31(5):941. PubMed ID: 24696218
[TBL] [Abstract][Full Text] [Related]
13. Expression of Livin, an antiapoptotic protein, is an independent favorable prognostic factor in childhood acute lymphoblastic leukemia.
Choi J; Hwang YK; Sung KW; Lee SH; Yoo KH; Jung HL; Koo HH; Kim HJ; Kang HJ; Shin HY; Ahn HS
Blood; 2007 Jan; 109(2):471-7. PubMed ID: 16990595
[TBL] [Abstract][Full Text] [Related]
14. Upregulation of the proto-oncogene Bmi-1 predicts a poor prognosis in pediatric acute lymphoblastic leukemia.
Peng HX; Liu XD; Luo ZY; Zhang XH; Luo XQ; Chen X; Jiang H; Xu L
BMC Cancer; 2017 Jan; 17(1):76. PubMed ID: 28122538
[TBL] [Abstract][Full Text] [Related]
15. Mutations in TP53 and JAK2 are independent prognostic biomarkers in B-cell precursor acute lymphoblastic leukaemia.
Forero-Castro M; Robledo C; Benito R; Bodega-Mayor I; Rapado I; Hernández-Sánchez M; Abáigar M; Maria Hernández-Sánchez J; Quijada-Álamo M; María Sánchez-Pina J; Sala-Valdés M; Araujo-Silva F; Kohlmann A; Luis Fuster J; Arefi M; de Las Heras N; Riesco S; Rodríguez JN; Hermosín L; Ribera J; Camos Guijosa M; Ramírez M; de Heredia Rubio CD; Barragán E; Martínez J; Ribera JM; Fernández-Ruiz E; Hernández-Rivas JM
Br J Cancer; 2017 Jul; 117(2):256-265. PubMed ID: 28557976
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of Tet methylcytosine dioxygenase 2 (TET2) gene mutations in adult patients with acute myeloid leukemia: a meta-analysis.
Liu WJ; Tan XH; Luo XP; Guo BP; Wei ZJ; Ke Q; He S; Cen H
Leuk Lymphoma; 2014 Dec; 55(12):2691-8. PubMed ID: 24524305
[TBL] [Abstract][Full Text] [Related]
17. The long-term results of childhood acute lymphoblastic leukemia at two centers from Turkey: 15 years of experience with the ALL-BFM 95 protocol.
Güneş AM; Oren H; Baytan B; Bengoa SY; Evim MS; Gözmen S; Tüfekçi O; Karapınar TH; Irken G
Ann Hematol; 2014 Oct; 93(10):1677-84. PubMed ID: 24863691
[TBL] [Abstract][Full Text] [Related]
18. Clinical, molecular, and prognostic correlates of number, type, and functional localization of TET2 mutations in chronic myelomonocytic leukemia (CMML)-a study of 1084 patients.
Coltro G; Mangaonkar AA; Lasho TL; Finke CM; Pophali P; Carr R; Gangat N; Binder M; Pardanani A; Fernandez-Zapico M; Robertson KD; Bosi A; Droin N; Vannucchi AM; Tefferi A; Hunter A; Padron E; Solary E; Patnaik MM
Leukemia; 2020 May; 34(5):1407-1421. PubMed ID: 31836856
[TBL] [Abstract][Full Text] [Related]
19. Expression and prognosis analysis of
Zhang T; Zhao Y; Zhao Y; Zhou J
Aging (Albany NY); 2020 Mar; 12(6):5031-5047. PubMed ID: 32209730
[No Abstract] [Full Text] [Related]
20. TET2 mutations in acute myeloid leukemia (AML): results from a comprehensive genetic and clinical analysis of the AML study group.
Gaidzik VI; Paschka P; Späth D; Habdank M; Köhne CH; Germing U; von Lilienfeld-Toal M; Held G; Horst HA; Haase D; Bentz M; Götze K; Döhner H; Schlenk RF; Bullinger L; Döhner K
J Clin Oncol; 2012 Apr; 30(12):1350-7. PubMed ID: 22430270
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
